UNSPSC 51263112: Bucindolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E9UO06K7CE, chemically known as 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)benzonitrile but generally known as bucindolol, which bears US NIH Compound Identifier 51045. Bucindolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Bucindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05945MIG.

UNSPSC 51263112 Bucindolol is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The single recent opportunity on file—Seminole County, Florida's IFB60459723LAS posted June 30, 2026—solicits Naloxone and Safe Drug Deactivation Systems, which fall outside the scope of this pharmaceutical agent code. The mismatch suggests either a tagging error in the source data or that the code is not actively used for relevant state and local procurements at this time.

Seminole County's IFB calls for annual purchase of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The county issued the IFB on an unspecified date with a response deadline of July 26, 2023, at 2:00 pm; vendors must include all shipping and delivery costs in their bids and comply with drug-free workplace certification, E-Verify, and federal environmental regulations potentially tied to FEMA funding. The contract offers an initial two-year term with a one-year renewal option and a three-month probationary termination clause. Beyond this single Seminole County opportunity, the code shows no recent state and local activity. Business development professionals should verify whether this code correctly represents their product or service line before targeting procurements under it.